FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006171475> ?p ?o ?g. }

• W2006171475 endingPage "807" @default.
• W2006171475 startingPage "799" @default.
• W2006171475 abstract "To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients.A 12-week double-blind, placebo-controlled clinical trial.An international study conducted at 167 medical centers.One thousand fifteen patients (43.1% aged > or =65) with urge incontinence and urinary frequency.Patients were randomized to treatment with tolterodine ER 4 mg once daily (qd) (n = 507) or placebo (n = 508) for 12 weeks.Efficacy, measured with micturition charts (incontinence episodes, micturitions, volume voided per micturition) and subjective patient assessments, safety, and tolerability endpoints were evaluated, relative to placebo, according to two age cohorts: younger than 65 and 65 and older.Mean age in the older and younger patient cohorts was 74 (range 65-93) and 51 (range 20-64), respectively. Compared with placebo, significant improvements in micturition chart variables with tolterodine ER showed no age-related differences. Irrespective of age, significantly more tolterodine ER recipients than placebo recipients reported an improvement in urgency symptoms. After 12 weeks of treatment with tolterodine ER, a fivefold increase in the percentage of patients able to finish tasks before voiding in response to urgency was noted in both age groups (<65: from 6.5-32.8%, > or =65: from 5.1-26.2%). Tolterodine ER recipients, irrespective of age, also had significant improvements in their bladder condition than did placebo recipients. Overall, a greater percentage of patients, irrespective of age, perceived any benefit with tolterodine ER than with placebo (P <.001). Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (<65: ER 22.7%, placebo 8.1%; > or =65: ER 24.3%, placebo 7.2%). Few patients (<2%) experienced severe dry mouth. No central nervous system, visual, cardiac (per electrocardiogram), or laboratory safety concerns were noted. Withdrawal rates due to adverse events on tolterodine ER 4 mg qd were comparable in the two age cohorts (<65: 5.5%; > or =65: 5.1%; P =.87).The new, once-daily ER formulation of tolterodine is efficacious, safe, and well tolerated in the treatment of patients with symptoms of overactive bladder, irrespective of age." @default.
• W2006171475 created "2016-06-24" @default.
• W2006171475 creator A5004707135 @default.
• W2006171475 creator A5037636679 @default.
• W2006171475 creator A5074586285 @default.
• W2006171475 date "2002-05-01" @default.
• W2006171475 modified "2023-10-18" @default.
• W2006171475 title "Efficacy, Safety, and Tolerability of Extended-Release Once-Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients" @default.
• W2006171475 cites W12330039 @default.
• W2006171475 cites W1591365506 @default.
• W2006171475 cites W1600603445 @default.
• W2006171475 cites W1982589773 @default.
• W2006171475 cites W1986143238 @default.
• W2006171475 cites W1994441135 @default.
• W2006171475 cites W2001559281 @default.
• W2006171475 cites W2005182544 @default.
• W2006171475 cites W2010109877 @default.
• W2006171475 cites W2021702941 @default.
• W2006171475 cites W2023548731 @default.
• W2006171475 cites W2024975356 @default.
• W2006171475 cites W2026522667 @default.
• W2006171475 cites W2026599479 @default.
• W2006171475 cites W2030052255 @default.
• W2006171475 cites W2033187059 @default.
• W2006171475 cites W2058646317 @default.
• W2006171475 cites W2058823225 @default.
• W2006171475 cites W2062242064 @default.
• W2006171475 cites W2074323366 @default.
• W2006171475 cites W2088679190 @default.
• W2006171475 cites W2093378550 @default.
• W2006171475 cites W2114253034 @default.
• W2006171475 cites W2134928141 @default.
• W2006171475 cites W2148567690 @default.
• W2006171475 cites W4293765665 @default.
• W2006171475 doi "https://doi.org/10.1046/j.1532-5415.2002.50203.x" @default.
• W2006171475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12028164" @default.
• W2006171475 hasPublicationYear "2002" @default.
• W2006171475 type Work @default.
• W2006171475 sameAs 2006171475 @default.
• W2006171475 citedByCount "157" @default.
• W2006171475 countsByYear W20061714752012 @default.
• W2006171475 countsByYear W20061714752013 @default.
• W2006171475 countsByYear W20061714752014 @default.
• W2006171475 countsByYear W20061714752015 @default.
• W2006171475 countsByYear W20061714752016 @default.
• W2006171475 countsByYear W20061714752017 @default.
• W2006171475 countsByYear W20061714752018 @default.
• W2006171475 countsByYear W20061714752019 @default.
• W2006171475 countsByYear W20061714752020 @default.
• W2006171475 countsByYear W20061714752022 @default.
• W2006171475 countsByYear W20061714752023 @default.
• W2006171475 crossrefType "journal-article" @default.
• W2006171475 hasAuthorship W2006171475A5004707135 @default.
• W2006171475 hasAuthorship W2006171475A5037636679 @default.
• W2006171475 hasAuthorship W2006171475A5074586285 @default.
• W2006171475 hasConcept C126322002 @default.
• W2006171475 hasConcept C126894567 @default.
• W2006171475 hasConcept C142724271 @default.
• W2006171475 hasConcept C175768497 @default.
• W2006171475 hasConcept C197934379 @default.
• W2006171475 hasConcept C204787440 @default.
• W2006171475 hasConcept C27081682 @default.
• W2006171475 hasConcept C2778375690 @default.
• W2006171475 hasConcept C2778531004 @default.
• W2006171475 hasConcept C2778941218 @default.
• W2006171475 hasConcept C2781020410 @default.
• W2006171475 hasConcept C71924100 @default.
• W2006171475 hasConcept C77411442 @default.
• W2006171475 hasConceptScore W2006171475C126322002 @default.
• W2006171475 hasConceptScore W2006171475C126894567 @default.
• W2006171475 hasConceptScore W2006171475C142724271 @default.
• W2006171475 hasConceptScore W2006171475C175768497 @default.
• W2006171475 hasConceptScore W2006171475C197934379 @default.
• W2006171475 hasConceptScore W2006171475C204787440 @default.
• W2006171475 hasConceptScore W2006171475C27081682 @default.
• W2006171475 hasConceptScore W2006171475C2778375690 @default.
• W2006171475 hasConceptScore W2006171475C2778531004 @default.
• W2006171475 hasConceptScore W2006171475C2778941218 @default.
• W2006171475 hasConceptScore W2006171475C2781020410 @default.
• W2006171475 hasConceptScore W2006171475C71924100 @default.
• W2006171475 hasConceptScore W2006171475C77411442 @default.
• W2006171475 hasIssue "5" @default.
• W2006171475 hasLocation W20061714751 @default.
• W2006171475 hasLocation W20061714752 @default.
• W2006171475 hasOpenAccess W2006171475 @default.
• W2006171475 hasPrimaryLocation W20061714751 @default.
• W2006171475 hasRelatedWork W1983371621 @default.
• W2006171475 hasRelatedWork W1983573081 @default.
• W2006171475 hasRelatedWork W1996534025 @default.
• W2006171475 hasRelatedWork W2001645992 @default.
• W2006171475 hasRelatedWork W2019380449 @default.
• W2006171475 hasRelatedWork W2050061619 @default.
• W2006171475 hasRelatedWork W2065591897 @default.
• W2006171475 hasRelatedWork W2084288786 @default.
• W2006171475 hasRelatedWork W2089437227 @default.
• W2006171475 hasRelatedWork W2341135423 @default.
• W2006171475 hasVolume "50" @default.
• W2006171475 isParatext "false" @default.

• next